FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal

🟢 FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitation: Axsome said up to 76% of patients with Alzheimer’s disease have agitation, which is characterized by pacing, restlessness and verbal or physical ...